VEGF-C downregulation reduces murine lung and colon cancer metastases, and Flt4/VEGFR-3 inhibition has been associated with reduced angiogenesis/lymphangiogenic activities as well as reduced growth and metastasis in breast, pancreatic, and ovarian cancers, paving the way for the development and testing of VEGFR3 inhibitors as targeted chemotherapeutics [44]. The gene discussed is FLT4; the disease is colonic neoplasm.